Cargando…

How has the field of metastatic breast cancer in bones evolved over the past 22 years?

BACKGROUND: Although knowledge on metastatic breast cancer in bones (MBCB) has increased rapidly over the past 22 years, a comprehensive and objective bibliometric analysis is still lacking. MATERIALS AND METHODS: We used R, VOSviewer, and Citespace software to conduct a bibliometric analysis of 5,4...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi, Guo, Zhen-Ning, He, Rong-Quan, Huang, Zhi-Guang, Luo, Jia-Yuan, Tang, Wei, Huang, Su-Ning, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209145/
https://www.ncbi.nlm.nih.gov/pubmed/37251089
http://dx.doi.org/10.1016/j.jbo.2023.100480
_version_ 1785046814832984064
author Chen, Yi
Guo, Zhen-Ning
He, Rong-Quan
Huang, Zhi-Guang
Luo, Jia-Yuan
Tang, Wei
Huang, Su-Ning
Chen, Gang
author_facet Chen, Yi
Guo, Zhen-Ning
He, Rong-Quan
Huang, Zhi-Guang
Luo, Jia-Yuan
Tang, Wei
Huang, Su-Ning
Chen, Gang
author_sort Chen, Yi
collection PubMed
description BACKGROUND: Although knowledge on metastatic breast cancer in bones (MBCB) has increased rapidly over the past 22 years, a comprehensive and objective bibliometric analysis is still lacking. MATERIALS AND METHODS: We used R, VOSviewer, and Citespace software to conduct a bibliometric analysis of 5,497 papers on MBCB from the Web of Science Core Collection (WOSCC) using author, institution, country/region, citation, and keyword indicators. RESULTS: A general strong sense of scholarly collaboration was noted in the MBCB field at the author, research institution, and country/region levels. We discovered some outstanding authors and highly productive institutions, but with less collaboration with other academic groups. Unbalanced and uncoordinated developments were observed among countries/regions in the field of MBCB research. We also found that by using various indicators and applying different analysis methods to them, we were able to broadly identify primary clinical practices, relevant clinical experiments, and directions for bioinformatics regarding MBCB, changes over the past 22 years, and current challenges in the field. The development of knowledge on MBCB is progressing greatly; however, MBCB is still incurable. CONCLUSION: This study is the first to use bibliometrics to provide an overall analysis of the scientific output of MBCB studies. Palliative therapies for MBCB are mostly in a mature state. However, research on the molecular mechanisms and immune response to tumors related to the development of treatments to cure MBCB remains relatively immature. Therefore, further research should be undertaken in this area.
format Online
Article
Text
id pubmed-10209145
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102091452023-05-26 How has the field of metastatic breast cancer in bones evolved over the past 22 years? Chen, Yi Guo, Zhen-Ning He, Rong-Quan Huang, Zhi-Guang Luo, Jia-Yuan Tang, Wei Huang, Su-Ning Chen, Gang J Bone Oncol Research Paper BACKGROUND: Although knowledge on metastatic breast cancer in bones (MBCB) has increased rapidly over the past 22 years, a comprehensive and objective bibliometric analysis is still lacking. MATERIALS AND METHODS: We used R, VOSviewer, and Citespace software to conduct a bibliometric analysis of 5,497 papers on MBCB from the Web of Science Core Collection (WOSCC) using author, institution, country/region, citation, and keyword indicators. RESULTS: A general strong sense of scholarly collaboration was noted in the MBCB field at the author, research institution, and country/region levels. We discovered some outstanding authors and highly productive institutions, but with less collaboration with other academic groups. Unbalanced and uncoordinated developments were observed among countries/regions in the field of MBCB research. We also found that by using various indicators and applying different analysis methods to them, we were able to broadly identify primary clinical practices, relevant clinical experiments, and directions for bioinformatics regarding MBCB, changes over the past 22 years, and current challenges in the field. The development of knowledge on MBCB is progressing greatly; however, MBCB is still incurable. CONCLUSION: This study is the first to use bibliometrics to provide an overall analysis of the scientific output of MBCB studies. Palliative therapies for MBCB are mostly in a mature state. However, research on the molecular mechanisms and immune response to tumors related to the development of treatments to cure MBCB remains relatively immature. Therefore, further research should be undertaken in this area. Elsevier 2023-04-10 /pmc/articles/PMC10209145/ /pubmed/37251089 http://dx.doi.org/10.1016/j.jbo.2023.100480 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Chen, Yi
Guo, Zhen-Ning
He, Rong-Quan
Huang, Zhi-Guang
Luo, Jia-Yuan
Tang, Wei
Huang, Su-Ning
Chen, Gang
How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title_full How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title_fullStr How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title_full_unstemmed How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title_short How has the field of metastatic breast cancer in bones evolved over the past 22 years?
title_sort how has the field of metastatic breast cancer in bones evolved over the past 22 years?
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209145/
https://www.ncbi.nlm.nih.gov/pubmed/37251089
http://dx.doi.org/10.1016/j.jbo.2023.100480
work_keys_str_mv AT chenyi howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT guozhenning howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT herongquan howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT huangzhiguang howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT luojiayuan howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT tangwei howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT huangsuning howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years
AT chengang howhasthefieldofmetastaticbreastcancerinbonesevolvedoverthepast22years